BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 12115517)

  • 1. Ipriflavone inhibits osteolytic bone metastasis of human breast cancer cells in a nude mouse model.
    Iwasaki T; Mukai M; Tsujimura T; Tatsuta M; Nakamura H; Terada N; Akedo H
    Int J Cancer; 2002 Aug; 100(4):381-7. PubMed ID: 12115517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiogenesis inhibitor TNP-470 inhibits human breast cancer osteolytic bone metastasis in nude mice through the reduction of bone resorption.
    Sasaki A; Alcalde RE; Nishiyama A; Lim DD; Mese H; Akedo H; Matsumura T
    Cancer Res; 1998 Feb; 58(3):462-7. PubMed ID: 9458090
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The bisphosphonate ibandronate promotes apoptosis in MDA-MB-231 human breast cancer cells in bone metastases.
    Hiraga T; Williams PJ; Mundy GR; Yoneda T
    Cancer Res; 2001 Jun; 61(11):4418-24. PubMed ID: 11389070
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Inhibition by interleukin 18 of osteolytic bone metastasis by human breast cancer cells.
    Nakata A; Tsujimura T; Sugihara A; Okamura H; Iwasaki T; Shinkai K; Iwata N; Kakishita E; Akedo H; Terada N
    Anticancer Res; 1999; 19(5B):4131-8. PubMed ID: 10628364
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bisphosphonate risedronate reduces metastatic human breast cancer burden in bone in nude mice.
    Sasaki A; Boyce BF; Story B; Wright KR; Chapman M; Boyce R; Mundy GR; Yoneda T
    Cancer Res; 1995 Aug; 55(16):3551-7. PubMed ID: 7627963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RANKL inhibition combined with tamoxifen treatment increases anti-tumor efficacy and prevents tumor-induced bone destruction in an estrogen receptor-positive breast cancer bone metastasis model.
    Canon J; Bryant R; Roudier M; Branstetter DG; Dougall WC
    Breast Cancer Res Treat; 2012 Oct; 135(3):771-80. PubMed ID: 22926264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-tumor effect in human breast cancer by TAE226, a dual inhibitor for FAK and IGF-IR in vitro and in vivo.
    Kurio N; Shimo T; Fukazawa T; Takaoka M; Okui T; Hassan NM; Honami T; Hatakeyama S; Ikeda M; Naomoto Y; Sasaki A
    Exp Cell Res; 2011 May; 317(8):1134-46. PubMed ID: 21338601
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The heat shock protein 90 inhibitor, 17-allylamino-17-demethoxygeldanamycin, enhances osteoclast formation and potentiates bone metastasis of a human breast cancer cell line.
    Price JT; Quinn JM; Sims NA; Vieusseux J; Waldeck K; Docherty SE; Myers D; Nakamura A; Waltham MC; Gillespie MT; Thompson EW
    Cancer Res; 2005 Jun; 65(11):4929-38. PubMed ID: 15930315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of osteolytic bone metastasis of breast cancer by combined treatment with the bisphosphonate ibandronate and tissue inhibitor of the matrix metalloproteinase-2.
    Yoneda T; Sasaki A; Dunstan C; Williams PJ; Bauss F; De Clerck YA; Mundy GR
    J Clin Invest; 1997 May; 99(10):2509-17. PubMed ID: 9153295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cathepsin K inhibitor reduces breast cancer induced osteolysis and skeletal tumor burden.
    Le Gall C; Bellahcène A; Bonnelye E; Gasser JA; Castronovo V; Green J; Zimmermann J; Clézardin P
    Cancer Res; 2007 Oct; 67(20):9894-902. PubMed ID: 17942921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sagopilone inhibits breast cancer bone metastasis and bone destruction due to simultaneous inhibition of both tumor growth and bone resorption.
    Strube A; Hoffmann J; Stepina E; Hauff P; Klar U; Käkönen SM
    Clin Cancer Res; 2009 Jun; 15(11):3751-9. PubMed ID: 19470728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trolox inhibits osteolytic bone metastasis of breast cancer through both PGE2-dependent and independent mechanisms.
    Lee JH; Kim B; Jin WJ; Kim JW; Kim HH; Ha H; Lee ZH
    Biochem Pharmacol; 2014 Sep; 91(1):51-60. PubMed ID: 24929117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model.
    Mbalaviele G; Dunstan CR; Sasaki A; Williams PJ; Mundy GR; Yoneda T
    Cancer Res; 1996 Sep; 56(17):4063-70. PubMed ID: 8752180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential effect of doxorubicin and zoledronic acid on intraosseous versus extraosseous breast tumor growth in vivo.
    Ottewell PD; Deux B; Mönkkönen H; Cross S; Coleman RE; Clezardin P; Holen I
    Clin Cancer Res; 2008 Jul; 14(14):4658-66. PubMed ID: 18628481
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis.
    Morony S; Capparelli C; Sarosi I; Lacey DL; Dunstan CR; Kostenuik PJ
    Cancer Res; 2001 Jun; 61(11):4432-6. PubMed ID: 11389072
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypoxia and hypoxia-inducible factor-1 expression enhance osteolytic bone metastases of breast cancer.
    Hiraga T; Kizaka-Kondoh S; Hirota K; Hiraoka M; Yoneda T
    Cancer Res; 2007 May; 67(9):4157-63. PubMed ID: 17483326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of hyaluronan oligosaccharides for bone metastasis of breast cancer.
    Urakawa H; Nishida Y; Knudson W; Knudson CB; Arai E; Kozawa E; Futamura N; Wasa J; Ishiguro N
    J Orthop Res; 2012 Apr; 30(4):662-72. PubMed ID: 21913222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transcutaneous carbon dioxide application suppresses bone destruction caused by breast cancer metastasis.
    Takemori T; Kawamoto T; Ueha T; Toda M; Morishita M; Kamata E; Fukase N; Hara H; Fujiwara S; Niikura T; Kuroda R; Akisue T
    Oncol Rep; 2018 Oct; 40(4):2079-2087. PubMed ID: 30066936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice.
    Weber KL; Doucet M; Price JE; Baker C; Kim SJ; Fidler IJ
    Cancer Res; 2003 Jun; 63(11):2940-7. PubMed ID: 12782601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A bone-seeking clone exhibits different biological properties from the MDA-MB-231 parental human breast cancer cells and a brain-seeking clone in vivo and in vitro.
    Yoneda T; Williams PJ; Hiraga T; Niewolna M; Nishimura R
    J Bone Miner Res; 2001 Aug; 16(8):1486-95. PubMed ID: 11499871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.